GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps
- Design
- Narrative review · None outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclearUNKNOWN: a narrative appraisal with no study population of its own; most of the evidence it covers comes from cell and animal studies, and no age, BMI or diabetes data are given.
- Could weight loss explain it?
- PossiblyNo weight, HbA1c or mediation data are reported, so any effect is presumed to be confounded with weight and metabolic change.
- Study tier
- Not ratedNOT_RATED: a narrative critical appraisal that adds no new primary data and pools nothing.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This is a narrative appraisal of what is known about GLP-1 receptor agonists and dental and oral health. Lab and animal studies suggest anti-inflammatory and bone-protective effects on gum and implant tissue, but clinical data come from a single retrospective cohort. Drug-safety report databases describe dry mouth, taste changes and loss of smell, and stomach side effects may pose a risk to teeth that has not been measured. No prospective study has used a dental outcome.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- not reported in abstract
- Primary outcome
- oral and dental health effects of GLP-1 receptor agonists (periodontal, peri-implant, oral adverse effects)
- Effect
- No pooled estimate. Preclinical studies show anti-inflammatory and osteoprotective effects on periodontal and peri-implant tissues; pharmacovigilance analyses report xerostomia, dysgeusia and anosmia; no prospective study has a dental endpoint.
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Oral adverse effects reported in pharmacovigilance analyses (xerostomia, dysgeusia, anosmia), particularly for semaglutide; nausea, vomiting and gastroesophageal reflux pose a plausible but unquantified risk of tooth erosion and secondary caries.
- Limitations
- A narrative appraisal with no new data. The clinical evidence it draws on is one retrospective cohort; the rest is in vitro and animal work, and no prospective study has used a dental endpoint.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- not reported in abstract
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- UNKNOWN
- Statistical precision
- no CI reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
GLP-1RAs (glucagon-like peptide-1 receptor agonists) have become one of the fastest-growing drug classes worldwide, with prescriptions for obesity treatment increasing by 587% from 2019 to 2024. While their metabolic and cardiovascular benefits are well established, the implications for oral health remain largely unexamined. Preclinical evidence consistently demonstrates anti-inflammatory and osteoprotective effects on periodontal and peri-implant tissues: GLP-1RAs promote osteogenic differentiation of periodontal ligament stem cells, reduce alveolar bone resorption in animal models of periodontitis, and enhance implant osseointegration in diabetic rats. However, these findings are based exclusively on in vitro and animal studies, with only a single retrospective cohort study providing limited clinical data. Conversely, several oral adverse effects have been reported based on pharmacovigilance analyses, including xerostomia, dysgeusia, and anosmia, particularly for semaglutide. Gastrointestinal side effects, particularly nausea (15% to 50%), vomiting (5% to 24%), and gastroesophageal reflux, pose a plausible but unquantified risk for tooth erosion and secondary caries. A bidirectional link between GLP-1 signaling and the oral microbiota, mediated by bacterial dipeptidyl peptidase (DPP)-4-like enzymes that degrade endogenous GLP-1, adds further complexity. Despite this breadth of potential interactions, no prospective study has used any dental outcome as an endpoint in patients receiving GLP-1RAs. This critical appraisal synthesizes the evidence across multiple dental disciplines, grades it in each domain, and identifies the gaps that demand urgent investigation.